# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Illumina, Inc. (NASDAQ:ILMN) today announced the release of its novel 5-base solution, enabling researchers to pursue broader b...
Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its p...
Evercore ISI Group analyst Vijay Kumar maintains Illumina (NASDAQ:ILMN) with a Outperform and lowers the price target from $...
New business focuses on developing data assets, software, and AI to fuel life science breakthroughsExpands pharma access to lar...
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—includ...
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarkerSAN DIEGO, Sept. 23, 2...
https://www.genomeweb.com/sequencing/element-biosciences-sues-illumina-alleging-anticompetitive-behavior-patent-infringement
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...